Efficiency and toxicity of hypofractionated radiotherapy with concurrent gemcitabine in the treatment of muscle-invasive bladder cancer (retrospective study) | ||||
| SECI Oncology Journal | ||||
| Volume 11, Issue 3, July 2023, Page 179-187 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Objectives: The objective was to calculate the toxicity of modified hypofractionated radiation combined with gemcitabine as well as local control, disease free survival (DFS), overall survival (OS), and bladder preservation rate in patient with muscle invasive bladder cancer (MIBC). Methods: Weekly 100 mg/m2 doses of gemcitabine were utilized as a radio- sensitizer. 30-minute intravenous infusion two to four hours before radiation treatment. Patients were treated with a hypo-fractionated radiation schedule utilizing a SIEMENS Linear accelerator over the course of four weeks and twenty-eight days, delivering 5250 cGy/20 fractions at 262.5 cGy per fraction. Results: In the 82 cases of bladder cancer that were examined, we observed a significantly lower frequency of patients who suffered frequent urination (p=0.002), urgency (p=0.001), and proctitis (p=0.031) when comparing early and late toxicities. An overall bladder preservation rate of 87.8% is achieved in the majority of the analyzed cases (87.7%), with a regressive course in 59.8%, a stationary course in 28.0%, and a progressive course in ten cases (12.2%). Patients had a median follow-up time of 56 months after a 5-year observation period. (Range, 1 month to 8 years). At 94 months, the OS rate was 84.3% and at 93 months, the DFS rate was 82.8%. Conclusion: Good efficacy and acceptable tolerability for a weekly, low-dose gemcitabine with hypofractionated radiation regimen in MIBC patients. | ||||
| Keywords | ||||
| gemcitabine; radio-sensitizer; hypofractionated radiotherapy; MIBC; TCRH | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 39 |
||||
